Google's life sciences unit to become a separate company under Alphabet

24 August 2015
2019_biotech_test_vial_discovery_big

Google (Nasdaq: GOOG) has announced it is segregating its life sciences unit into an independent company under the newly created parent group Alphabet.

The company’s life sciences group will graduate from the Google X labs and become a standalone company under Alphabet, Google co-founder Sergey Brin said.

“While the reporting structure will be different, their goal remains the same. They’ll continue to work with other life sciences companies to move new technologies from early stage R&D to clinical testing - and, hopefully - transform the way we detect, prevent, and manage disease,” Mr Brin said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology